Holen Sie sich die Stockscreener-App
48.27
1.90%
-0.6852
Schlusskurs vom Vortag:
$48.96
Offen:
$49.04
24-Stunden-Volumen:
49,468
Relative Volume:
0.08
Marktkapitalisierung:
$2.57B
Einnahmen:
$15.13M
Nettoeinkommen (Verlust:
$-44.05M
KGV:
-29.62
EPS:
-1.63
Netto-Cashflow:
$-47.75M
1W Leistung:
-6.01%
1M Leistung:
-4.87%
6M Leistung:
+5.58%
1J Leistung:
+452.07%
1-Tages-Spanne:
$47.74
$49.78
1-Wochen-Bereich:
$47.04
$51.09
52-Wochen-Spanne:
$7.79
$65.60
Janux Therapeutics Inc Stock (JANX) Company Profile
Firmenname
Janux Therapeutics Inc
Sektor
Branche
Telefon
(858) 751-4493
Adresse
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Vergleichen Sie JANX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| JANX | 48.34 | 2.57B | 15.13M | -44.05M | -47.75M | -1.63 |
| VRTX | 446.01 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 736.92 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 587.24 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.39 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-06 | Eingeleitet | Wedbush | Outperform |
| 2022-11-14 | Eingeleitet | William Blair | Outperform |
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Janux Therapeutics’ Q3 Report: Financials and Progress - TipRanks
Stifel Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN
Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation - Seeking Alpha
Bitdeer Technologies, PBF Energy, and More Stocks See Action From Activist Investors - Barron's
Long Term Trading Analysis for (JANX) - Stock Traders Daily
FMR LLC's Strategic Acquisition of Janux Therapeutics Shares - GuruFocus.com
William Blair Predicts Lower Earnings for Janux Therapeutics - Defense World
HC Wainwright Has Negative Outlook of JANX FY2024 Earnings - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
What is HC Wainwright's Forecast for JANX FY2024 Earnings? - MarketBeat
William Blair Issues Pessimistic Forecast for JANX Earnings - MarketBeat
Janux Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Janux Therapeutics earnings missed by $0.18, revenue fell short of estimates - Investing.com UK
Janux Therapeutics price target raised to $82 from $62 at BTIG - TipRanks
Janux Therapeutics Cash Soars to $658M Despite Widening Q3 Losses; Trial Updates Ahead | JANX Stock News - StockTitan
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
Nisa Investment Advisors LLC Has $924,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Stock Price Up 6.3%Here's Why - MarketBeat
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Bath & Body Works, Paramount Global, and More Stocks See Action From Activist Investors - Barron's
2024's 10 Best-Performing Stocks | Investing - U.S News & World Report Money
Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) Price Target at $66.44 - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Janux Therapeutics CEO sells shares worth $1.34 million By Investing.com - Investing.com Australia
Janux Therapeutics CEO sells shares worth $1.34 million - Investing.com
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
This Insider Has Just Sold Shares In Janux Therapeutics - Simply Wall St
Warren Buffett Back for More, Plus Big Insider Buying at Biotechs Too - 24/7 Wall St.
Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at UBS Group - Defense World
Keros Therapeutics (NASDAQ:KROS) Now Covered by Cantor Fitzgerald - Defense World
UBS Initiates Coverage of Janux Therapeutics (JANX) with Buy Recommendation - MSN
Janux therapeutics sees significant stock sale by major shareholder Jay Lichter for $178,084 - Investing.com
Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials - openPR
Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics - Barchart
Janux Therapeutics stock offers upside on T cell engager platform, says UBS - Investing.com Canada
Cracking The Code: Understanding Analyst Reviews For Janux Therapeutics - Benzinga
Janux Therapeutics (NASDAQ:JANX) Receives New Coverage from Analysts at UBS Group - MarketBeat
Paradigm Biocapital Advisors LP Acquires Shares in Janux Therape - GuruFocus.com
RA Capital Management Reduces Stake in Janux Therapeutics - GuruFocus.com
Insider Buying: Janux Therapeutics, Inc. (NASDAQ:JANX) Director Purchases 1,200,000 Shares of Stock - MarketBeat
Ra Capital Management buys $53.7 million in Janux Therapeutics stock By Investing.com - Investing.com Nigeria
Ra Capital Management buys $53.7 million in Janux Therapeutics stock - Investing.com
Vanguard S&P 500 Growth ETF (NYSEARCA:VOOG) Shares Sold by Cwm LLC - Defense World
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by SG Americas Securities LLC - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 1,843 Shares - MarketBeat
Janux therapeutics sees $23.8 million in stock sales By Investing.com - Investing.com Australia
Janux therapeutics sees $23.8 million in stock sales - Investing.com
Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
0.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):